Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

A Duchenne Breakthrough Awaits In 2023 - But Risks Remain For Sarepta And US FDA

Gene Therapy Could Be Launched Mid-2023

Dec 06 2022

• By Andrew McConaghie

Sarepta Building 2

Related Content

With Sarepta’s Vyondys, US FDA Staff Saw Opportunity To Right Perceived Wrongs With Exondys

Jan 27 2020

Spotlight On High Doses Again After Pfizer Duchenne Gene Therapy Death

Dec 23 2021

UniQure/CSL Set To Launch First Hemophilia B Gene Therapy Next Year At Record Price

Nov 23 2022

Blenrep US Withdrawal Is A Big Blow To GSK’s Blockbuster Hopes

Nov 22 2022

Related Companies

Sarepta Therapeutics, Inc.

Hansa Biopharma AB

uniQure N.V.

Roche Holding AG

Additional Topics

Approvals Companies Commercial Regulation Research & Development FDA Neurology BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window